Supplementary Table 4.
Plasma LM Profiles Post Albumin Administration
| DHA bioactive metabolome | Q1 | Q3 | Group 1 |
Group 2 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2-2529 AOB | 3-2445 AOB | 8-1822 AOB | 9-2417 AOB | 10-2200 AOB | 5-1026 AOB | 4-1486 AOB | 1-2320 AOB | 6-2419 AOB | 7-1702 AOB | |||
| RvD1 | 375 | 141 | 0.3 | — | 0.4 | 2.1 | 1.1 | — | 2.5 | 9.4 | 0.4 | 3.4 |
| RvD2 | 375 | 141 | — | 0.6 | 2.5 | — | 3.6 | — | 4.6 | — | 2.7 | 7.4 |
| RvD3 | 375 | 147 | — | 0.7 | — | 6.7 | — | 3.4 | 3.1 | 0.8 | 0.4 | — |
| RvD4 | 375 | 101 | 0.1 | 1.4 | 2.2 | 1.9 | 3.6 | 0.4 | 0.6 | 2.4 | 0.9 | 0.9 |
| RvD5 | 359 | 199 | 3.6 | 3.6 | 5.6 | 14.1 | 18.2 | 7.4 | 7.8 | 1.6 | 7.5 | 17.5 |
| RvD6 | 359 | 101 | 4.5 | 2.8 | 3.3 | 0.6 | 6.2 | 24.7 | 31.7 | 2.7 | 10.2 | 1.8 |
| 17R-RvD1 | 375 | 141 | — | 1.7 | — | 1.0 | — | — | — | — | 1.2 | 1.2 |
| 17R-RvD3 | 375 | 147 | 0.2 | — | — | 0.5 | — | 0.3 | — | 1.0 | — | 2.8 |
| PD1 | 359 | 153 | 1.3 | 2.1 | 0.3 | 1.1 | 2.1 | — | — | 2.8 | 4.9 | 8.8 |
| 17R-PD1 | 359 | 153 | 5.1 | 3.9 | — | 1.5 | 3.4 | — | — | — | — | 1.5 |
| 10S,17S-diHDHA | 359 | 153 | — | — | — | — | 0.9 | — | — | — | 0.6 | — |
| 22-OH-PD1 | 375 | 153 | — | — | — | — | 0.2 | — | 1.2 | 2.7 | — | 1.2 |
| MaR1 | 359 | 221 | — | — | — | — | 1.7 | 2.9 | — | — | — | — |
| 7S,14S-diHDHA | 359 | 221 | 3.1 | — | 1.9 | 20.0 | 3.2 | — | — | 8.6 | 3.2 | — |
| 4S,14S-diHDHA | 359 | 101 | — | — | 1.6 | 6.6 | — | — | — | 19.5 | — | 3.8 |
| n-3 DPA bioactive metabolome | ||||||||||||
| RvT1 | 377 | 239 | 0.5 | 0.5 | 0.6 | 0.5 | 0.5 | 7.4 | 1.7 | 0.7 | 0.8 | 8.8 |
| RvT2 | 377 | 197 | 0.2 | 1.0 | 1.1 | — | 1.1 | 1.4 | 0.8 | 2.5 | 1.5 | — |
| RvT3 | 377 | 197 | 0.6 | 0.3 | 0.6 | — | 0.8 | — | 0.6 | 3.8 | 0.3 | 2.7 |
| RvT4 | 377 | 211 | 2.8 | 1.5 | 2.0 | — | 1.9 | — | 4.2 | 15.7 | 1.2 | 10.7 |
| RvD1n-3 DPA | 377 | 143 | 16.7 | 20.3 | 7.5 | 15.3 | 9.1 | 4.8 | 4.5 | 18.9 | 9.2 | 3.2 |
| RvD2n-3 DPA | 377 | 215 | — | 0.2 | — | 1.1 | 2.7 | 1.0 | 1.1 | 3.2 | — | 1.8 |
| RvD5n-3 DPA | 361 | 199 | 3.7 | 9.3 | — | 3.3 | 0.8 | 8.5 | — | 3.2 | 2.5 | 4.6 |
| PD1n-3 DPA | 361 | 183 | 24.4 | 47.3 | 299.5 | 108.5 | 41.5 | 574.0 | 422.6 | — | — | 367.1 |
| 10S,17S-diHDPA | 361 | 183 | — | — | — | — | — | — | — | — | — | — |
| MaR1n-3 DPA | 361 | 223 | — | 4.7 | 10.3 | 78.1 | 2.7 | — | 13.0 | — | — | 109.7 |
| 7S, 14S-diHDPA | 361 | 223 | — | 6.5 | 9.7 | 81.7 | — | — | 84.7 | — | 1.8 | 39.2 |
| EPA bioactive metabolome | ||||||||||||
| RvE1 | 349 | 195 | 0.9 | — | 0.5 | 0.5 | 0.4 | 25.4 | 5.4 | 1.0 | 8.7 | 0.6 |
| RvE2 | 333 | 199 | 3.9 | — | 1.9 | 1.2 | 1.0 | 207.1 | 39.1 | 4.3 | 32.3 | 2.5 |
| RvE3 | 333 | 201 | 0.8 | 4.0 | 13.3 | — | — | — | 3.5 | — | 2.9 | 181.5 |
| AA bioactive metabolome | ||||||||||||
| LXA4 | 351 | 217 | 0.7 | — | — | 0.4 | — | 1.5 | 0.4 | — | 1.5 | 0.7 |
| LXB4 | 351 | 221 | 13.5 | 6.8 | 6.8 | 11.0 | 189.1 | 0.0 | 11.0 | 189.1 | 0.0 | 13.5 |
| 5S,15S-diHETE | 335 | 235 | 58.8 | 182.7 | 47.9 | 71.2 | 21.4 | 282.4 | 126.7 | 58.6 | 11.0 | 45.2 |
| AT-LXA4 | 351 | 217 | — | — | — | 3.5 | — | 17.6 | 3.5 | — | 17.6 | — |
| AT-LXB4 | 351 | 221 | — | — | — | — | — | 129.3 | — | — | 129.3 | — |
| LTB4 | 335 | 195 | 8.4 | 12.4 | 4.6 | 11.2 | 52.4 | 20.5 | 15.2 | 6.7 | 84.2 | 85.5 |
| 5S,12S-diHETE | 335 | 195 | 13.2 | 4.3 | 2.0 | 11.2 | 52.4 | 5.7 | 10.3 | 8.1 | 56.8 | 4.2 |
| 20-OH-LTB4 | 351 | 195 | 15.6 | 4.2 | — | — | — | 19.5 | 5.2 | 26.5 | 129.3 | — |
| LTC4 | 626 | 189 | 310.6 | 143.6 | 104.0 | 108.4 | 29.1 | 67.5 | 187.3 | 71.6 | 86.1 | 158.3 |
| LTD4 | 497 | 189 | — | — | 181.7 | — | — | — | — | — | 11.8 | — |
| LTE4 | 440 | 189 | 16.3 | 15.4 | 111.6 | 115.8 | 0.4 | 560.8 | 29.6 | 12.3 | 54.9 | — |
| PGD2 | 351 | 189 | 21.2 | 34.8 | 26.8 | 13.9 | 47.3 | 36.9 | 13.5 | 14.5 | 27.4 | 32.8 |
| PGE2 | 351 | 189 | 58.9 | 55.4 | 71.8 | 8.2 | 69.4 | 69.5 | 25.1 | 3.8 | 72.0 | 65.1 |
| PGF2α | 353 | 193 | 28.0 | 92.6 | 114.2 | 41.4 | 107.8 | 65.6 | 58.1 | 37.6 | 31.6 | 84.8 |
| TxB2 | 369 | 169 | 3167.6 | 938.9 | 9291.8 | 943.0 | 4320.1 | 1790.9 | 3309.4 | 782.5 | 8298.5 | 5740.6 |
NOTE. LM levels were assessed using LM-metabololipidomics. Results are expressed as pg/mL. Em dash = below limit; limit ≈ 0.1 pg. With Q1, M-H (parent ion); and Q3, diagnostic ion in the tandem mass spectrometry (daughter ion).
AA, arachidonic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; LM, lipid mediator; PG, prostaglandin.